Zhongguo shi yan xue ye xue za zhi · 2026
[Clinical Characteristics Analysis of Primary Gastric Large B-Cell Lymphoma with IRF4 Rearrangement].
СтатьяКлинический случайАннотация на английскомНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gu Chang-Ying, He He-Sheng, Huang Chen, Yao Jun-Ping, Wang Su-Fen, Jiang Hua
Аннотация
OBJECTIVE: To investigate the clinical characteristics and diagnostic approaches for patients with primary gastric large B-cell lymphoma with IRF4 rearrangements (LBCL-IRF4), thereby enhancing understanding of this distinct subtype.
METHODS: A retrospective analysis was conducted on the clinical presentation, diagnostic and therapeutic course, and prognosis of this single case of primary gastric LBCL-IRF4 treated in our hospital.
RESULTS: Based on pathological, imaging, and bone marrow examinations, the patient was diagnosed with LBCL-IRF4 (Stage ⅡA, IPI score: 1, low risk; NCCN-IPI score: 2, intermediate-low risk; CNS score: 1, low risk). The patient received four cycles of the R-CDOP regimen (rituximab + cyclophosphamide + vindersine + liposomal doxorubicin + prednisolone tablets) followed by two additional cycles of rituximab consolidation therapy. The patient achieved complete remission.
CONCLUSION: LBCL-IRF4 is clinically uncommon, and primary gastric LBCL-IRF4 is even rare. Such patients demonstrate favourable outcomes following standard treatment.
METHODS: A retrospective analysis was conducted on the clinical presentation, diagnostic and therapeutic course, and prognosis of this single case of primary gastric LBCL-IRF4 treated in our hospital.
RESULTS: Based on pathological, imaging, and bone marrow examinations, the patient was diagnosed with LBCL-IRF4 (Stage ⅡA, IPI score: 1, low risk; NCCN-IPI score: 2, intermediate-low risk; CNS score: 1, low risk). The patient received four cycles of the R-CDOP regimen (rituximab + cyclophosphamide + vindersine + liposomal doxorubicin + prednisolone tablets) followed by two additional cycles of rituximab consolidation therapy. The patient achieved complete remission.
CONCLUSION: LBCL-IRF4 is clinically uncommon, and primary gastric LBCL-IRF4 is even rare. Such patients demonstrate favourable outcomes following standard treatment.